GHRS peer analysis
GH Research (GHRS) against its competitors: price, today's move, 1-year return and market value side by side.
GHRS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ANRO Alto Neuroscience | $29.66 | -3.14% | 108.87% | $1.19B |
| BHVN Biohaven | $13.81 | -1.85% | 73.71% | $2.09B |
| DFTX Definium Therapeutics | $32.09 | -2.76% | – | $4.39B |
| LBRX LB Pharmaceuticals | $42.95 | 1.15% | 184.81% | $1.39B |
| MPLT MapLight Therapeutics | $7.25 | 2.55% | -49.86% | $329.42M |
| NERV Minerva Neurosciences | $2.38 | -7.03% | -40.50% | $118.61M |
| NMRA Neumora Therapeutics | $0.43 | -8.46% | -84.86% | $81.36M |
| RAPP Rapport Therapeutics | $26.12 | 1.04% | 3.77% | $1.25B |
| SPTX Seaport Therapeutics | $19.95 | -0.89% | – | $1.07B |
| VTGN Vistagen Therapeutics | $0.18 | -4.79% | -95.61% | $7.93M |
| GHRS GH Research | $19.12 | 3.41% | 27.47% | $1.31B |
- GHRS's peers: ANRO (Alto Neuroscience), BHVN (Biohaven), DFTX (Definium Therapeutics), LBRX (LB Pharmaceuticals), MPLT (MapLight Therapeutics), NERV (Minerva Neurosciences), NMRA (Neumora Therapeutics), RAPP (Rapport Therapeutics).
Updated 2026-11-14 00:53 UTC